Gdansk

• A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea … Ended
  2023-504156-10-00 5 2021-08-13 Plaque Psoriasis.
• Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Und … Ended
  2024-515056-20-00 5 2021-07-31 Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoin
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 5 2021-07-26 Severe asthma with an eosinophilic phenotype
• Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathi … Ended
  2024-515964-30-00 4 2021-07-14 Interstitial Lung Diseases (ILD), including but not limited to idiopat
• Metoprolol Safety and Efficacy in the Prevention of Cardiomyopathy in Patients with Duchenne Muscular Dystrophy (DMD) Ended
  2024-515057-19-00 5 2021-07-12 Duchenne muscular dystrophy; Cardiomyopathy; Tachycardia
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M … Ended
  2023-506315-17-00 9 2021-06-25 Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naiv
• A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended
  2023-503280-42-00 5 2021-06-01 Metastatic Clear Cell Renal Cell Carcinoma
• A Study of BMS-986012 in Combination with Carboplatin, Etoposide, andNivolumab as First-line Therapy in Extensive-stage Small Cell Lung Canc … Ended
  2024-510700-36-00 4 2021-06-01 Extensive-stage Small Cell Lung Cancer
• Phase 2 study of Pembrolizumab given every 6 weeks to participants diagnosed with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL … Ended
  2024-510979-38-00 4 2021-05-27 Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or ref
• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1 P … Ended
  2023-509449-10-00 4 2021-03-16 Squamous cell carcinoma of the head and neck (SCCHN)
• A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust … Ended
  2023-504977-19-00 5 2021-03-15 Moderately to Severely Active Ulcerative Colitis
• GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Ended
  2023-507086-26-00 7 2021-03-09 Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell L
• A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma … Ended
  2024-512686-13-00 3 2021-01-28 non-Hodgkin lymphoma and chronic lymphocytic leukemia
• Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Ended
  2024-512652-38-00 4 2021-01-25 Cutaneous Squamous Cell Carcinoma
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Substudy to test investigational agents with pembrolizumab in combination with chemotherapy in treatment-naïve NSCLC in a rolling arm design Ended
  2023-506932-33-00 4 2020-10-20 non-small cell lung cancer
• Substudy to test investigational agents in combination with pembrolizumab in PD-L1 positive treatment-naïve NSCLC in a rolling arm design Ended
  2023-506933-32-00 4 2020-10-20 Non-small Cell Lung Cancer (NSCLC)
• Substudy to test investigational agents in combination with pembrolizumab in patients with PD-(L)1 refractory NSCLC in a rolling-arm design Ended
  2023-506934-56-00 4 2020-10-20 Non-small Cell Lung Cancer
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended
  2023-507303-55-00 4 2020-09-30 Alzheimer Disease
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK … Ended
  2023-506313-21-00 9 2020-08-03 PD-1 refractory melanoma
• A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensiv … Ended
  2022-502988-37-00 5 2020-06-19 Small cell lung cancer (SCLC)

Showing 793–816 of 854 trials